Skip to main content

Table 1 Age and gender for patients with acromegaly receiving octreotide or lanreotide

From: Treatment adherence and persistence with long-acting somatostatin analog therapy for the treatment of acromegaly: a retrospective analysis

  All patients Patients with a 180-day washout period
Therapy Variable N Mean SD N Mean SD
Octreotide Age at first injection (yr) 1127 50.6 11.1 545 51.4 11.2
% of male patients 1127 45.9% 0.5 545 48.1% 0.5
Lanreotide Age at first injection (yr) 181 45.9 11.9 118 45.7 11.7
% of male patients 181 45.9% 0.5 118 44.9% 0.5
  1. N sample size, SD standard deviation